Key result
Statin treatment normalizes monocyte phenotype in severe hypercholesterolemia but lowers granular protein secretion.
Why the study?
Does 12 months of statin treatment normalize monocyte and neutrophil phenotypes in patients with severe hypercholesterolemia compared to normocholesterolemic controls?
Cross-Sectional
Does 12 months of statin treatment normalize monocyte and neutrophil phenotypes in patients with severe hypercholesterolemia compared to normocholesterolemic controls?
Answers are grounded in this paper and cite their sources.
Long-term (12-month) statin therapy in severe hypercholesterolemia appears to normalize the hyperresponsive monocyte phenotype previously observed in treatment-naïve patients.
Background and aims: Hypercholesterolemia is a major risk factor for atherosclerotic cardiovascular disease. Innate immune cells, including monocytes and neutrophils, play important roles in the pathophysiology of atherosclerosis. We previously reported that monocytes from patients with severely elevated low-density lipoprotein (LDL) cholesterol (LDL-c > 4.9 mmol/l) have a hyperresponsive phenotype, which persists even after three months statin treatment. This long-term hyperresponsive innate immune phenotype is termed trained immunity (innate immune memory), and is mediated by persistent enrichment of activating histone modifications leading to higher chromatin accessibility. In this study we investigated the monocyte and neutrophil phenotype of patients with severe hypercholesterolemia treated for 12 months with statins, compared to normocholesterolemic controls. Methods: promotor. In addition, we assessed the neutrophil phenotype and function. Results: promotor did not differ from the controls (LDL-c 2.6 mmol/L). Although neutrophil CD11b, CD66b, and CD62L expression was the same, production of several granular proteins was lower in patients. Conclusions: Previous studies reported hyperresponsive monocytes in treatment-naïve patients with LDL-c > 4.9 mmol/l. We now demonstrate that in an independent cohort of patients with LDL-c > 4.9 who are treated for 12 months with lipid-lowering drugs, the monocyte phenotype and function was similar to that of normocholesterolemic controls. In addition, neutrophils phenotype was similar, while the secretion of several granular proteins was lower in the patients.
No takes yet. Share an insight, caveat, or question.
Bahrar et al. (2025) conducted a cross-sectional in Severe hypercholesterolemia. Statin treatment vs. Normocholesterolemic controls was evaluated on Monocyte and neutrophil phenotype and function. Patients with severe hypercholesterolemia treated with statins for 12 months had similar monocyte phenotypes to controls, but lower granular protein secretion.
Synapse has enriched 10 related papers. Consider them for comparative context: